Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer
/in International Publications, NSCLC /von 2009-09-13 / Gen Thorac Cardiovasc Surg 2009 Sep;57(9):449-57Mechanisms of murine dendritic cell antitumor dysfunction in aging
/in International Publications, Malignant Melanoma, NSCLC /von 2008-12-13 / Cancer Immunol. Immunother. 2009 Dec;58(12):1935-9Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
/in International Publications, NSCLC /von 2008-12-04 / Lung Cancer 2009 Jul;65(1):1-8Inoperable Pancoast tumors treated with hyperthermia-inclusive multimodality therapies
/in International Publications, NSCLC /von 2008-07-11 / Lung Cancer 2009 Feb;63(2):247-50Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors
/in International Publications, Newcastle Disease Virus, NSCLC /von 2008-06-06 / Cancer Gene Ther. 2008 Dec;15(12):795-807Antitumor effect of lung cancer vaccine with umbilical blood dendritic cells in reconstituted SCID mice
/in International Publications, NSCLC /von 2008-06-01 / Cancer Biother. Radiopharm. 2008 Jun;23(3):321-31IFN-gamma down-regulates Hsp27 and enhances hyperthermia-induced tumor cell death in vitro and tumor suppression in vivo
/in International Publications, NSCLC /von 2008-06-01 / Int. J. Oncol. 2008 Jun;32(6):1317-24Radiotherapy with 8-MHz radiofrequency-capacitive regional hyperthermia for stage III non-small-cell lung cancer: the radiofrequency-output power correlates with the intraesophageal temperature and clinical outcomes
/in International Publications, NSCLC /von 2008-05-29 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):128-35Hyperthermia switches glucose depletion-induced necrosis to apoptosis in A549 lung adenocarcinoma cells
/in International Publications, NSCLC /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):851-60
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives